<SEC-DOCUMENT>0001104659-25-048564-index.html : 20250514 <SEC-HEADER>0001104659-25-048564.hdr.sgml : 20250514 <ACCEPTANCE-DATETIME>20250514163954 ACCESSION NUMBER: 0001104659-25-048564 CONFORMED SUBMISSION TYPE: 424B3 PUBLIC DOCUMENT COUNT: 21 FILED AS OF DATE: 20250514 DATE AS OF CHANGE: 20250514 FILER: COMPANY DATA: COMPANY CONFORMED NAME: GLYCOMIMETICS INC CENTRAL INDEX KEY: 0001253689 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 424B3 SEC ACT: 1933 Act SEC FILE NUMBER: 333-285035 FILM NUMBER: 25946512 BUSINESS ADDRESS: STREET 1: 9708 MEDICAL CENTER DRIVE CITY: ROCKVILLE STATE: MD ZIP: 20850 BUSINESS PHONE: 240-243-1201 MAIL ADDRESS: STREET 1: 9708 MEDICAL CENTER DRIVE CITY: ROCKVILLE STATE: MD ZIP: 20850 </SEC-HEADER> <DOCUMENT> <TYPE>424B3 <SEQUENCE>1 <FILENAME>tm256615-16_424b3.htm <DESCRIPTION>424B3 <TEXT> Document 1 - file: tm256615-16_424b3.htm
</DOCUMENT> <DOCUMENT> <TYPE>GRAPHIC <SEQUENCE>2 <FILENAME>lg_glycomimetics-4c.jpg <DESCRIPTION>GRAPHIC <TEXT> Document 2 - file: lg_glycomimetics-4c.jpg
</DOCUMENT> <DOCUMENT> <TYPE>GRAPHIC <SEQUENCE>3 <FILENAME>lg_crescent-4clr.jpg <DESCRIPTION>GRAPHIC <TEXT> Document 3 - file: lg_crescent-4clr.jpg
</DOCUMENT> <DOCUMENT> <TYPE>GRAPHIC <SEQUENCE>4 <FILENAME>bc_paidvstsr-4c.jpg <DESCRIPTION>GRAPHIC <TEXT> Document 4 - file: bc_paidvstsr-4c.jpg
</DOCUMENT> <DOCUMENT> <TYPE>GRAPHIC <SEQUENCE>5 <FILENAME>bc_paidvsnetincome-4c.jpg <DESCRIPTION>GRAPHIC <TEXT> Document 5 - file: bc_paidvsnetincome-4c.jpg
</DOCUMENT> <DOCUMENT> <TYPE>GRAPHIC <SEQUENCE>6 <FILENAME>bc_inhibitors-4c.jpg <DESCRIPTION>GRAPHIC <TEXT> Document 6 - file: bc_inhibitors-4c.jpg
</DOCUMENT> <DOCUMENT> <TYPE>GRAPHIC <SEQUENCE>7 <FILENAME>lc_nsclc-4clr.jpg <DESCRIPTION>GRAPHIC <TEXT> Document 7 - file: lc_nsclc-4clr.jpg
</DOCUMENT> <DOCUMENT> <TYPE>GRAPHIC <SEQUENCE>8 <FILENAME>tb_pfs-4c.jpg <DESCRIPTION>GRAPHIC <TEXT> Document 8 - file: tb_pfs-4c.jpg
</DOCUMENT> <DOCUMENT> <TYPE>GRAPHIC <SEQUENCE>9 <FILENAME>ph_vegf-4clr.jpg <DESCRIPTION>GRAPHIC <TEXT> Document 9 - file: ph_vegf-4clr.jpg
</DOCUMENT> <DOCUMENT> <TYPE>GRAPHIC <SEQUENCE>10 <FILENAME>ph_cr001-4clr.jpg <DESCRIPTION>GRAPHIC <TEXT> Document 10 - file: ph_cr001-4clr.jpg
</DOCUMENT> <DOCUMENT> <TYPE>GRAPHIC <SEQUENCE>11 <FILENAME>lc_cooperative-4c.jpg <DESCRIPTION>GRAPHIC <TEXT> Document 11 - file: lc_cooperative-4c.jpg
</DOCUMENT> <DOCUMENT> <TYPE>GRAPHIC <SEQUENCE>12 <FILENAME>ph_antivegf-4c.jpg <DESCRIPTION>GRAPHIC <TEXT> Document 12 - file: ph_antivegf-4c.jpg
</DOCUMENT> <DOCUMENT> <TYPE>GRAPHIC <SEQUENCE>13 <FILENAME>tb_clinicaldevelop-4c.jpg <DESCRIPTION>GRAPHIC <TEXT> Document 13 - file: tb_clinicaldevelop-4c.jpg
</DOCUMENT> <DOCUMENT> <TYPE>GRAPHIC <SEQUENCE>14 <FILENAME>fc_chemotherapy-4clr.jpg <DESCRIPTION>GRAPHIC <TEXT> Document 14 - file: fc_chemotherapy-4clr.jpg
</DOCUMENT> <DOCUMENT> <TYPE>GRAPHIC <SEQUENCE>15 <FILENAME>fc_cr002adc-4c.jpg <DESCRIPTION>GRAPHIC <TEXT> Document 15 - file: fc_cr002adc-4c.jpg
</DOCUMENT> <DOCUMENT> <TYPE>GRAPHIC <SEQUENCE>16 <FILENAME>lg_lucidcapital-bwlr.jpg <DESCRIPTION>GRAPHIC <TEXT> Document 16 - file: lg_lucidcapital-bwlr.jpg
</DOCUMENT> <DOCUMENT> <TYPE>GRAPHIC <SEQUENCE>17 <FILENAME>ft_lucidcapnewyork-bw.jpg <DESCRIPTION>GRAPHIC <TEXT> Document 17 - file: ft_lucidcapnewyork-bw.jpg
</DOCUMENT> <DOCUMENT> <TYPE>GRAPHIC <SEQUENCE>18 <FILENAME>sg_lucidcapitalmarkets-bw.jpg <DESCRIPTION>GRAPHIC <TEXT> Document 18 - file: sg_lucidcapitalmarkets-bw.jpg
</DOCUMENT> <DOCUMENT> <TYPE>GRAPHIC <SEQUENCE>19 <FILENAME>lg_walkers-bwlr.jpg <DESCRIPTION>GRAPHIC <TEXT> Document 19 - file: lg_walkers-bwlr.jpg
</DOCUMENT> <DOCUMENT> <TYPE>GRAPHIC <SEQUENCE>20 <FILENAME>px_glycoproxy1pg01-bw.jpg <DESCRIPTION>GRAPHIC <TEXT> Document 20 - file: px_glycoproxy1pg01-bw.jpg
</DOCUMENT> <DOCUMENT> <TYPE>GRAPHIC <SEQUENCE>21 <FILENAME>px_glycoproxy1pg02-bw.jpg <DESCRIPTION>GRAPHIC <TEXT> Document 21 - file: px_glycoproxy1pg02-bw.jpg
</DOCUMENT> </SEC-DOCUMENT>